Summer Sale
50% off Premium Yearly
NASDAQ:HRMY
Harmony Biosciences Holdings Inc (HRMY)
Financials 
Technical Analysis 
Jun 11, 2026, 12:00 amThis summary was created by AI, based on 3 opinions in the last 12 months.
Harmony Biosciences Holdings Inc (HRMY) has garnered attention from analysts with its focus on neurological treatments and a promising development pipeline. The company has triggered a stop-loss at $33 for those involved in trading but is still highlighted as a 'Top Pick' due to its potential for growth, particularly in the treatment for narcolepsy. The analysts note its valuation metrics, including a 14x earnings multiple, which indicates a reasonable investment opportunity given the company's expanding cash reserves and decreasing debt. With a recommended trailing stop and price targets ranging from $49 to $50, there appears to be a significant upside potential seen by experts. Overall, HRMY is positioned as a strong candidate for investors seeking exposure in the pharmaceutical space, especially in the cannabis-derived treatment sector.
;fill-opacity:1;'/%3e%3cpath%20d='M31%2018.6001V30H8V18.6001L14.1334%2022.4334L19.4999%2014L24.8669%2022.4334L31%2018.6001Z'%20fill='%23EE5432'%20style='fill:%23EE5432;fill:color(display-p3%200.9340%200.3310%200.1956);fill-opacity:1;'/%3e%3c/svg%3e){kind=small}
Premium contentWe reiterate this commercial stage pharma company focusing on neurological treatment as a TOP PICK. It has a long runway of projects in the development pipeline and its histamine focused foundation treatment continues to create positive cash flow and growing cash reserves. We recommend trailing up the stop (from $30) to $33, looking to achieve $50 -- upside potential of 33%. Yield 0%
(Analysts’ price target is $50.55)Premium contentHRMY is a bio-pharma company that has developed cannabis based CBD gels in the US. It is making potentially great strides on developing a treatment for narcolepsy. It trades at 14x earnings, 2.8x book and supports a 24% ROE. Cash reserves are growing, while debt is retired. We recommend setting a stop-loss at $30, looking to achieve $49 -- upside potential of 37%. Yield 0%
(Analysts’ price target is $49.70)- «
- ‹
- 1
- ›
- »
Harmony Biosciences Holdings Inc (HRMY) Frequently Asked Questions
What is Harmony Biosciences Holdings Inc stock symbol?
Harmony Biosciences Holdings Inc is a American stock, trading under the symbol HRMY (previously HRMY-Q on Stockchase) on the NASDAQ (HRMY). It is usually referred to as NASDAQ:HRMY or HRMY
Is Harmony Biosciences Holdings Inc a buy or a sell?
In the last year, 3 stock analysts issued a Buy, Sell, or Hold rating on HRMY (previously HRMY-Q on Stockchase). 3 analysts recommended to BUY and 0 analysts recommended to SELL the stock. The latest stock analyst rating is TOP PICK. Read the latest stock experts' ratings for Harmony Biosciences Holdings Inc.
Is Harmony Biosciences Holdings Inc a good investment or a top pick?
Harmony Biosciences Holdings Inc was recommended as a Top Pick by The Panic-Proof Portfolio (Stockchase Research) on 2025-07-17. Read the latest stock experts ratings for Harmony Biosciences Holdings Inc.
Why is Harmony Biosciences Holdings Inc stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Harmony Biosciences Holdings Inc.
Is Harmony Biosciences Holdings Inc worth watching?
Harmony Biosciences Holdings Inc is covered by Stockchase experts and is worth watching.
What is Harmony Biosciences Holdings Inc stock price?
On 2026-06-12, Harmony Biosciences Holdings Inc (HRMY) stock closed at a price of $34.46.
'%20fill='%23FFB800'%3e%3cg%20id='filled-.-button'%20transform='translate(120.000000,%20413.999972)'%3e%3cpath%20d='M101.499729,2.82302245e-05%20C102.285413,-0.00432461793%20103.254164,0.496634241%20103.645655,1.25173399%20L103.712109,1.39623206%20L105.747863,6.45331817%20L111.028779,6.80428588%20C111.60867,6.84282525%20112.147242,7.1236355%20112.517275,7.58038413%20C113.223405,8.45199453%20113.142035,9.72214747%20112.357105,10.4940033%20L112.234099,10.6059323%20L108.072656,14.10894%20L109.356339,19.592529%20C109.472157,20.0872738%20109.394126,20.6085551%20109.13883,21.0455786%20C108.624329,21.9263208%20107.536956,22.2447485%20106.649713,21.8010736%20L106.511398,21.7246573%20L101.5,18.7715858%20L96.4886024,21.7246573%20C95.5790916,22.2767096%2094.4027498,21.9726757%2093.8611695,21.0455786%20C93.6058745,20.6085551%2093.5278433,20.0872738%2093.6436608,19.592529%20L94.9273443,14.10894%20L90.7659013,10.6059323%20C89.8680707,9.85015912%2089.7412886,8.49557505%2090.4827254,7.58038413%20C90.8527577,7.1236355%2091.39133,6.84282525%2091.9712215,6.80428588%20L97.2521374,6.45331817%20L99.2878908,1.39623206%20C99.6240254,0.561228427%20100.665516,-0.00460395016%20101.499729,2.82302245e-05%20Z'%20id='top-picks-.-icon-copy-7'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e){kind=small}
Our PAST TOP PICK with HRMY has triggered its stop at $33. To remain disciplined, we recommend covering the position at this time.